Prognostic impact of TP53, ASXL1, and RUNX1 mutations in the ELN2017 adverse-risk group. In patients with adverse risk, the presence of a TP53 mutation associated with higher CIR (A) and shorter OS (B). In contrast, patients who harbored mutations in ASXL1 (C-D) or RUNX1 (E-F) had CIR and OS comparable to that of patients with adverse risk who lacked these mutations.